Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neurotech Pharmaceuticals
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Active (recurrent or persistent) subfoveal CNV lesions secondary to AMD in the study eye
Prior Intravitreal Anti-VEGF injections
You may not be if
Significant subretinal hemorrhage
Significant Scar and/or, fibrosis
Suspected polypoidal choroidopathy, or pigment epithelial tears or rips
Inadequate response to anti-VEGF therapy
Clareo Health | Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
